$2.4 billion settlement agreement reached in Actos bladder cancer litigation

April 29, 2015 - Takeda Pharmaceutical Co. has agreed to a $2.4 billion settlement to resolve bladder cancer claims tied to its Type 2 diabetes drug Actos. The settlement will compensate an anticipated... Read More

Actos verdict illustrates companies that co-promote drugs can be held liable for injuries, failure to warn

September 4, 2014 - A federal judge’s decision not to overturn a jury’s $9 billion verdict against Takeda Pharmaceutical Co. and Eli Lilly for withholding bladder cancer risks from doctors and patients... Read More

Federal jury orders drug makers Takeda, Eli Lilly to pay $9 billion for Actos cancer risk

April 8, 2014 - Jurors found Takeda Pharmaceutical Co. and Eli Lilly & Co. liable for a combined $9 billion in punitive damages after finding the drug makers hid cancer risks associated with Actos... Read More

Type 2 diabetes drugs may increase risk of pancreatic cancer

August 12, 2013 - A commonly prescribed class of Type 2 diabetes drugs known as incretin mimetics may put users at risk for developing pancreatic cancer, according to new research published in the British... Read More


June 30, 2011 - Actos (pioglitazone), manufactured by Takeda Pharmaceuticals and distributed by Eli Lilly and Company, has been under FDA review since September 2010. In June 2011, the FDA issued a warning... Read More

Diabetes drug Actos pulled from French, German markets due to cancer link

June 10, 2011 - Drug regulators in France and Germany have suspended the use of the diabetes drug pioglitazone – found in brand name drug Actos, manufactured by Takeda - in light of a recent study... Read More

back to top